Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better?

被引：187
作者：
Im H.-J. [1 ,2 ]
Bradshaw T. [1 ]
Solaiyappan M. [3 ]
Cho S.Y. [1 ,3 ,4 ]
机构：
[1] Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI
[2] Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Seoul
[3] Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD
[4] University of Wisconsin Carbone Cancer Center, Madison, WI
来源：
Nuclear Medicine and Molecular Imaging | 2018年 / 52卷 / 1期
基金：
新加坡国家研究基金会;
关键词：
!sup]18[!/sup]F-fluorodeoxyglucose; Metabolic tumor volume; Positron emission tomography; Segmentation; Tumor;
D O I：
10.1007/s13139-017-0493-6
中图分类号：
学科分类号：
摘要：
Numerous methods to segment tumors using 18F-fluorodeoxyglucose positron emission tomography (FDG PET) have been introduced. Metabolic tumor volume (MTV) refers to the metabolically active volume of the tumor segmented using FDG PET, and has been shown to be useful in predicting patient outcome and in assessing treatment response. Also, tumor segmentation using FDG PET has useful applications in radiotherapy treatment planning. Despite extensive research on MTV showing promising results, MTV is not used in standard clinical practice yet, mainly because there is no consensus on the optimal method to segment tumors in FDG PET images. In this review, we discuss currently available methods to measure MTV using FDG PET, and assess the advantages and disadvantages of the methods. © 2017, Korean Society of Nuclear Medicine.
引用
收藏
页码：5 / 15
页数：10
相关论文
共 65 条
  • [1] Vanderhoek M., Perlman S.B., Jeraj R., Impact of the definition of peak standardized uptake value on quantification of treatment response, J Nucl Med, 53, pp. 4-11, (2012)
  • [2] Larson S.M., Erdi Y., Akhurst T., Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis, Clin Positron Imaging, 2, pp. 159-171, (1999)
  • [3] Im H.J., Kim T.S., Park S.Y., Et al., Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma, Eur J Nucl Med Mol Imaging, 39, pp. 39-49, (2012)
  • [4] Im H.J., Kim Y.K., Kim Y.I., Lee J.J., Lee W.W., Kim S.E., Usefulness of combined metabolic-volumetric indices of (18)F-FDG PET/CT for the early prediction of neoadjuvant chemotherapy outcomes in breast cancer, Nucl Med Mol Imaging, 47, pp. 36-43, (2013)
  • [5] Lee J.W., Kang C.M., Choi H.J., Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative 18F-FDG PET/CT in patients with pancreatic cancer, J Nucl Med, 55, pp. 898-904, (2014)
  • [6] Byun B.H., Kong C.B., Lim I., Et al., Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential (1)(8)F-FDG PET/CT and MRI, Eur J Nucl Med Mol Imaging, 41, pp. 1553-1562, (2014)
  • [7] Cheebsumon P., van Velden F.H.P., Yaqub M., Et al., Effects of image characteristics on performance of tumor delineation methods: a test–retest assessment, J Nucl Med, 52, pp. 1550-1558, (2011)
  • [8] Moon S.H., Hyun S.H., Choi J.Y., Prognostic significance of volume-based PET parameters in cancer patients, Korean J Radiol, 14, pp. 1-12, (2013)
  • [9] Jh O., Choi W.H., Han E.J., Et al., The prognostic value of (18)F-FDG PET/CT for early recurrence in operable breast cancer: comparison with TNM stage, Nucl Med Mol Imaging, 47, pp. 263-267, (2013)
  • [10] Costelloe C.M., Macapinlac H.A., Madewell JE, et al. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma, J Nucl Med, 50, pp. 340-347, (2009)
1234567